Clinical Trial: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720375) titled 'A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis' on July 17.

Brief Summary: The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Non-cystic Fibrosis Bronchiectasis

Intervention: BIOLOGICAL: Galvokimig

Drug: Galvokimig Pharmaceutical form: Solution for injection

BIOLOGICAL: Placebo

Drug: Placebo Pharmaceutical f...